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Abstract Bone remodeling, the fundamental process for
bone renewal, is targeted by treatments of osteoporosis to
correct the imbalance between bone resorption and bone
formation and reduce the risk of fractures and associated
clinical consequences. Currently available therapeutics
affect bone resorption and bone formation in the same
direction and either decrease (inhibitors of bone resorption)
or increase (parathyroid hormone [PTH] peptides) bone
remodeling. Studies of patients with rare bone diseases and
genetically modified animal models demonstrated that
bone resorption and bone formation may not necessarily be
coupled, leading to identification of molecular targets in
bone cells for the development of novel agents for the
treatment of osteoporosis. Application of such agents to the
treatment of women with low bone mass confirmed that
bone resorption and bone formation can be modulated in
different directions and so far two new classes of thera-
peutics for osteoporosis have been defined with distinct
mechanisms of action. Such treatments, if combined with a
favorable safety profile, will offer new therapeutic options
and will improve the management of patients with
osteoporosis.
Key Points
In osteoporosis, there is an imbalance between bone
resorption and bone formation leading to bone loss
and structural decay of the skeleton.
Currently available therapeutics affect bone
resorption and bone formation in the same direction
and either decrease (inhibitors of bone resorption) or
increase (PTH peptides) bone remodeling.
New classes of therapeutics for osteoporosis with
different mechanisms of action are in clinical
development.
Inhibitors of Cathepsin K reduce bone resorption
while preserving bone formation and increase bone
mineral density at the spine and the hip continuously
for at least 5 years of treatment.
Inhibitors of sclerostin increase bone formation
while reducing bone resorption and impressively
increase bone mineral density at the spine and the
hip.
1 Introduction
Osteoporosis is characterized by reduced bone mass and
strength leading to increased risk of fractures. Pharmaco-
logical interventions aim to decrease this risk and the
associated clinical consequences by correcting the imbal-
ance between bone resorption and bone formation that
constitutes the pathophysiological basis of the disease.
Most currently available agents inhibit bone resorption and
& Socrates E. Papapoulos
S.E.Papapoulos@lumc.nl; m.v.iken@lumc.nl
1 Center for Bone Quality, Leiden University Medical Center,
Albinusdreef 2, 2333 ZA Leiden, The Netherlands
Drugs (2015) 75:1049–1058
DOI 10.1007/s40265-015-0417-7
formation to varying degrees and decrease the risk of
fractures but cannot replace already lost bone, and they
only modestly decrease the risk of non-vertebral fractures,
the most frequent osteoporotic fractures. Parathyroid hor-
mone (PTH) peptides, the only approved bone-forming
agents, stimulate bone formation but also bone resorption
and have not been shown to reduce the risk of hip fractures,
the most devastating clinical consequence of osteoporosis.
These unmet needs have led to efforts for the development
of new therapeutics for osteoporosis based on improved
knowledge of the local regulation of bone remodeling
arising mainly from the study of rare bone diseases and
genetically modified animal models [1]. We review here
the information that led to the rational design and clinical
application of new agents for the pharmacological man-
agement of osteoporosis.
2 General Considerations
Bone remodeling occurs in an orderly fashion by the basic
multicellular units (BMUs), temporary anatomical structures
comprising a team of osteoclasts in the front and a team of
osteoblasts in the back, supported by blood vessels, nerves, and
connective tissue. Osteoclasts resorb bone by removing bone
mineral and degrading the organic matrix, while osteoblasts
move to the resorbed area and lay down new bone matrix that
subsequently mineralizes, a process known as coupling. The
mechanisms regulating this coupling are not entirely clear but it
is thought that growth factors mobilized from the bone matrix
during resorptionmight contribute to intercellular signaling and
subsequent stimulation of bone formation. Alternatively or in
addition, the osteoclasts produce factors that might contribute
to generation and differentiation of osteoblast precursors [2, 3].
It is now generally accepted that osteocytes are the main reg-
ulators of bone remodeling due to their location in bone
allowing them to sense mechanical signals and to respond to
chemical signals regulating bone and mineral metabolism by
secreting factors that can modulate the number and function of
osteoblasts and osteoclasts [4–6].
An increased number and life span of osteoclasts and a
decrease in the formation and life span of osteoblasts induce
an imbalance between bone resorption and bone formation,
the cellular basis of osteoporosis. This imbalance, in favor of
resorption, results in bone loss and deterioration of bone
architecture. The decline in the ability of osteoblasts to refill
the resorption cavity leads to reduction of the thickness of the
bone packets and thinning of the trabeculae. In addition, the
enhanced osteoclastic resorption per unit time that occurs at
the menopause results in perforation and removal of tra-
beculae and loss of their connectivity [7]. Cortical bone
becomes wider in diameter and thinner, due to the move of
the endosteal surface outwards at a greater pace than bone
placed in the periosteum, but also more porotic due to
enhanced intracortical remodeling [8]. The net outcome of
these changes is increased bone fragility and this provides
the rationale for the development of agents for the pharma-
cological management of osteoporosis. It is clear from the
described changes that reduction of bone resorption must be
an essential component of any therapeutic approach for the
maintenance or improvement of bone strength. However,
this approach cannot replace already lost bone, which is
required for better fracture protection in women with severe
disease. For this, specific stimulation of bone formation is
essential. Thus, in theory, optimal pharmacological man-
agement of osteoporosis should aim at decreasing bone
resorption (endosteal and intracortical) and stimulating bone
formation at all skeletal envelopes, including the periosteum.
Such approach will not only prevent the structural decay of
bone tissue but will also increase bone mass and may lead to
improved reduction of the risk of non-vertebral fractures,
which occur predominantly at cortical bone sites.
3 Inhibitors of Bone Resorption
Inhibitors of osteoclastic bone resorption, such as bisphos-
phonates, denosumab and selective estrogen receptor modu-
lators (SERMs), reduce the rate of bone resorption to varying
degrees bydifferentmechanismsof action.The reductionof the
rate of bone resorption is invariably followed by reduction of
the rate of bone formation due to the coupling of the two pro-
cesses. The final result is an overall decrease of the rate of bone
turnover to a level that depends on the potency of the individual
agent used and is maintained during the whole period of
treatment. The introduction of themost potent inhibitor of bone
resorption, denosumab, into clinical practice made any further
development of this class of agents obsolete. However, studies
of humans and animals with osteopetrosis indicated that
reduction of bone resorption may not necessarily be coupled
with reducedbone formation if theosteoclasts remain intact [9].
Loss of function of a number of molecules regulating removal
of bonemineral or degradationofbonematrixwere shown tobe
associatedwith adecreaseofbone resorptionwithout, however,
affecting or even stimulating bone formation [10, 11].
Cathepsin K (CatK), a protease abundantly expressed in
osteoclasts responsible for the degradation of the organic
matrix of bone, is the most extensively studied molecule in
preclinical and clinical studies.
3.1 Cathepsin K Inhibitors
CatK is a member of a family of cysteine proteases that is
synthesized as a pro-enzyme before being transported to
lysosomes where it is cleaved to produce the active enzyme
that degrades collagen type I and other bone matrix proteins
1050 N. M. Appelman-Dijkstra, S. E. Papapoulos
within the acidic environment of resorption lacunae [12].
Congenital absence of CatK in patients with pycnodysosto-
sis, a rare, autosomal, recessive osteochondrodysplasia, is
characterized by increased bone density, bone deformities,
and increased bone fragility, complications that are not
present in heterozygotes [13]. CatK-deficient mice develop a
high bone mass phenotype in the presence of fully differ-
entiated osteoclasts, while mice over-expressing CatK had
increased bone turnover and decreased trabecular bone
volume [14, 15]. The discovery that loss of function of CatK
decreases bone resorption with increased number of viable
osteoclasts and the surprising finding of preservation or even
increase in bone formation provided the rationale for the
development of a new class of antiresorptive agents that
target this enzyme (Fig. 1) [16–18]. The mechanism
responsible for the maintenance or increase in bone forma-
tion in the presence of reduced bone resorption by CatK
inhibition may be due to stimulation of osteoblasts by
osteoclast-derived factors (clastokines, such as sphingosine-
1-phosphate) or matrix-derived growth factors (such as IGF-
1) that are not degraded [19, 20]. Initial studies of CatK
inhibitors showed off-target inhibition of other cathepsins
due either to their lack of specificity for CatK or to their
accumulation in lysosomes of cells other than osteoclasts and
led to the design of new agents potentially devoid of such
effects. Two CatK inhibitors are currently in clinical devel-
opment for the treatment of osteoporosis, namely odanacatib
(Merck & Co) and ONO-5334 (Ono Pharmaceutical
Fig. 1 Schematic representations of a the normal coupling process of
bone resorption and formation during the remodeling process.
RANKL promotes differentiation and activation of osteoclasts at
remodeling sites. Coupling factors derived from the resorbed bone
matrix or directly from the activated osteoclasts stimulate the
recruitment and maturation of osteoblasts to initiate bone formation
on the existing resorption surface. b Denosumab blocks osteoclasto-
genesis, and bisphosphonate induces the loss of ruffled border and
eventual osteoclast apoptosis. These therapies lead to little-to-no
resorption surface and fewer numbers of osteoclasts on bone.
c Treatment with a CatK inhibitor reduces osteoclastic resorption
efficiency and retards transcytotic trafficking of matrix removal. This
does not prevent other osteoclast functions, such as the generation of a
shallow resorption surface and the release of osteogenic factors;
together, these functions initiate osteoblast bone formation. BP
bisphosphonate, CatKi cathepsin K inhibitor, Ob osteoblast, OC
osteoclast, pOb osteoblast progenitor, pOC osteoclast progenitor,
RANK receptor activator of nuclear factor kappa-B, RANKL RANK
ligand. Reproduced with permission from [17]
Novel Treatments for Osteoporosis 1051
Company), which in phase II clinical trials had similar
effects on bone turnover and bone mineral density (BMD)
without any off-target effects. We will further discuss only
odanacatib, as an example of pharmacological inhibition of
CatK, because it is the only one tested so far in a phase III
clinical study.
Odanacatib is a selective, orally administered CatK
inhibitor [21]. Unlike basic CatK inhibitors, odanacatib is
neutral and does not accumulate in the acidic environment of
lysosomes which could lead to off-target inhibition of other
cathepsins [16, 22]. Odanacatib is metabolized by CYP3A4
and its absorption is not impaired by food intake [17, 23]. In
animal models, odanacatib reduced bone resorption while
preserving bone formation in trabecular and endocortical
surfaces. In addition, odanacatib reduced cortical remodel-
ing and increased modeling-based bone formation, and
improved the cortical area of the femur and its strength [24,
25]. Odanacatib was further superior to alendronate in
increasing cortical thickness, possibly through increased
periosteal bone formation, an action that was also observed
during treatment with another CatK inhibitor [26, 27].
A 2-year (with a 3-year extension) phase IIb dose-
finding clinical trial of postmenopausal women with low
bone mass identified 50 mg once weekly as the optimal
oral dose of odanacatib [28–30]. In this study, treatment
with odanacatib 50 mg once weekly reduced biochemical
markers of bone resorption by about 55 %, while markers
of bone formation were mildly and transiently reduced,
returning to baseline after about 2 years. Serum levels of
the osteoclast marker TRAP5b increased with treatment,
confirming osteoclast viability. These changes of bone
markers were associated with continuous increases in BMD
by 11.9 % at the spine and more importantly at the hip by
8.5 and 9.8 % at the total hip (TH) and femoral neck (FN),
respectively, after 5 years. Different from bisphosphonates
but similar to other antiresorptives, the effects of odana-
catib on bone turnover and BMD were rapidly reversible
upon discontinuation of treatment. Odanacatib treatment
exhibited a generally favorable safety and tolerability
profile, with incidence of adverse events similar to placebo.
In another 2-year, placebo-controlled study, the effects
of odanacatib on the cortical and trabecular compartments
and strength of bone were assessed by quantitative com-
puted tomography (QCT) and high-resolution QCT (HR-
QCT) in 214 postmenopausal women with low areal BMD
[31, 32]. As in the phase II study, odanacatib decreased
bone resorption, maintained bone formation, and increased
areal BMD. In addition, it increased volumetric BMD and
estimated bone strength of both the hip and the spine as
well as cortical and trabecular density, cortical thickness,
and estimated strength of the distal radius and distal tibia.
In this study, adverse effects were also similar between
placebo- and odanacatib-treated women.
The antifracture efficacy of odanacatib was examined in
the Long-Term Odanacatib Fracture Trial (LOFT), the
largest clinical trial in osteoporosis. LOFT is a phase III,
event-driven clinical trial, with a preplanned extension, of
women aged[65 years with osteoporosis [33]. Participants
had either a prior radiographic vertebral fracture and BMD
T-score B-1.5 at the FN or TH or no prior vertebral
fracture and BMD T-score B-2.5 at the FN or TH. The
trial was designed to test the hypothesis that treatment with
odanacatib 50 mg once weekly reduces the risk of new
morphometric vertebral, hip and non-vertebral fractures
(all primary endpoints) in postmenopausal women with
osteoporosis. Women were randomized in a 1:1 ratio to
receive placebo or odanacatib 50 mg once weekly. All
received weekly vitamin D3 (5600 IU) and daily calcium
supplements to ensure a daily intake of approximately
1200 mg. In July 2012, an independent Data Monitoring
Committee (DMC) recommended termination of the study
since odanacatib displayed a favorable benefit/risk profile
as well as efficacy relative to placebo. At the same time,
the DMC suggested that additional safety data should be
obtained in the preplanned blinded extension study.
The 16,071women included in the study had amean age of
72.8 years, 57 % were Caucasian and 46.5 % had prior ver-
tebral fracture.MeanBMDT-scoreswere: LS-2.7,TH-2.4,
and FN-2.7 and mean duration of follow-up was 34 months
[34]. Compared with placebo, treatment with odanacatib
decreased the incidence of new and worsening morphometric
vertebral fractures by 54 %, of hip fractures by 47 %, of non-
vertebral fractures by 23 % and of clinical fractures by 72 %
(all p\ 0.0001). Odanacatib treatment led to progressive
increases over 5 years in BMD at LS and TH: 11.2 and 9.5 %,
respectively, compared with placebo. Adverse events were
generally well balanced between groups. Adjudicated mor-
phea-like skin lesions occurred more frequently in odanacat-
ib-treated patients (12) compared with placebo (3) and
resolved/improved after study drug discontinuation. Adjudi-
cated femoral shaft fractures with atypical features occurred
only in odanacatib-treated patients (5), while no cases of ONJ
were reported. No meaningful differences between groups
were observed in adjudicated systemic sclerosis, respiratory
infections, or delayed fracture union. Major cardiovascular
events overall were generally balanced; however, there were
numerically more adjudicated strokes with odanacatib than
with placebo; final blinded adjudication of major cardiovas-
cular events is ongoing [35].
4 Stimulators of Bone Formation
The only currently available bone forming agent, PTH,
stimulates bone formation but also bone resorption. PTH
binds to the PTH/PTHrP type 1 receptor and activates
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several signaling pathways, including the canonical Wnt-
signaling pathway, having both anabolic and catabolic
effects on bone that are probably exerted via signaling in
osteocytes [36]. Teriparatide, given by daily subcutaneous
injections, increases cancellous and endocortical bone for-
mation, mainly at sites undergoing active bone remodeling,
but has limited effect on periosteal bone formation and
increases cortical porosity [37]. PTHrP 1–36 and its analog
abaloparatide, which bind to the PTH/PTHrP 1 receptor, also
increase bone formation and bone resorption markers, but to a
lesser extent than teriparatide, and improve hip BMD sig-
nificantly more than teriparatide [38, 39].
Concurrent treatment of women with osteoporosis with
teriparatide and the inhibitor of bone resorption, deno-
sumab, increased BMD at all skeletal sites considerably
more than either monotherapy alone after 2 years [40, 41].
The difference in response between teriparatide and teri-
paratide/denosumab treatment is probably due to inhibition
of teriparatide-stimulated RANKL (receptor activator of
nuclear factor kappa-B ligand) production by denosumab
that reduced bone resorption and allowed teriparatide to
exert a stimulatory effect only on bone formation. These
results reinforce the hypothesis that for optimal therapeutic
outcome, bone formation and bone resorption should be
modulated in different directions. The results of the studies
of CatK inhibitors illustrated that this may be feasible.
CatK inhibitors, however, may preserve bone formation but
are not anabolic agents, an important unmet need in the
management of osteoporosis.
The design of a genuine anabolic treatment for osteo-
porosis must address the possibility of stimulating bone
formation without concomitant stimulation of bone resorp-
tion and ensuring that formation is stimulated at quiescent
bone surfaces. Human and animal genetics indicated that
this may be feasible. In particular, the recognition of the
pivotal role of the Wnt signaling pathway in bone formation
provided a number of potential targets for the development
of new pharmaceuticals. For clinical use, however, treat-
ments should not only modify the expression of target
molecules but need also to have bone specificity to avoid
potential off-target effects [1, 42, 43]. One such target is
sclerostin, a negative regulator of bone formation produced
exclusively in the skeleton by osteocytes [44].
4.1 Sclerostin Inhibitors
The role of sclerostin in bone metabolism was identified in
studies of patients with sclerosteosis and van Buchem
disease, two rare sclerosing bone dysplasias with very
similar phenotypes and high bone mass [45]. These dis-
eases are characterized by progressive generalized over-
growth and thickening of bone that is resistant to fracture
[46]. The two conditions are due to different defects of the
SOST gene which is located on chromosome 17q12–21 and
encodes the protein sclerostin [47–50]. Both defects result
in impaired production of sclerostin leading to a dramatic
increase in bone mass in humans and mice, whereas mice
overexpressing sclerostin are osteopenic [51, 52].
Osteocyte-produced sclerostin is transported to the bone
surface through the osteocyte dendritic network where it
inhibits the proliferation, differentiation, and survival of
osteoblasts. Sclerostin also has an autocrine function and
upregulates RANKL synthesis in osteocytes, thereby
stimulating osteoclastogenesis [53] (Fig. 2). SOST has been
identified in the kidney, liver, and heart, but sclerostin
expression has not been identified in any of these tissues in
humans [45, 47, 48]. Sclerostin decreases bone formation
by antagonizing the canonical Wnt signaling pathway in
osteoblasts. It binds to the first propeller domain of the
LRP5/6 receptor, thereby disabling the formation of the co-
receptor complex between LRP5/6 and Frizzled receptor,
and inhibiting the Wnt pathway high up in the signaling
cascade [54]. The exact mechanism by which sclerostin
interacts with the LRP5/6 receptor remains to be estab-
lished but it is thought that it requires a co-factor to inhibit
the Wnt pathway similar to another Wnt antagonist, Dkk1,
which needs Kremen to inhibit the pathway. LRP4, pro-
duced by osteoblasts and early osteocytes, was recently








Fig. 2 Schematic representation of sclerostin actions. Osteocyte-pro-
duced sclerostin inhibits the proliferation, differentiation, and survival of
osteoblasts and reduces bone formation; it also stimulates the production
of RANKL by neighboring osteocytes and bone resorption. In
osteoblasts, sclerostin binds to LRP5/6 and inhibits the Wnt signaling
pathway, an action facilitated by LRP4. Production of sclerostin is
decreased by mechanical loading, PTH, estrogens and other factors, and
antisclerostin antibodies. LRP low-density lipoprotein receptor-related
protein,PTH parathyroid hormone,RANKL receptor activator of nuclear
factor kappa-B ligand
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sclerostin on bone formation, and mutations in LRP4 were
identified in patients with a phenotype closely resembling
that of sclerosteosis [53]. In addition, inhibition of LRP4
by a specific antibody increased the rate of bone formation
and bone mass in mice [55].
The restricted expressionof sclerostin in the skeleton and the
lack of abnormalities in organs other than the skeleton in
patients and animals with sclerostin deficiency made this pro-
tein an attractive target for the development of a new bone-
forming therapy for the management of osteoporosis. This
approach was further supported by studies of heterozygous
carriers of sclerosteosis who have increased serum levels of
P1NP and high, normal, or increased BMD but no clinical
symptoms, signs, or complications of sclerosteosis [46, 56].
Two inhibitors of sclerostin are currently being tested for the
treatment of osteoporosis; romosozumab or AMG 785 (hu-
manized monoclonal antibody, Amgen and UCB) and bloso-
zumab (humanized monoclonal antibody, Eli Lilly).
Romosozumab was used in most reported studies. In aged
ovariectomized rats and nonhuman primates, romosozumab
stimulated trabecular andcortical bone formation and increased
bone mass and strength [57, 58]. Importantly, the majority of
new bone formation induced by romosozumab was modeling-
based, occurring at quiescent surfaces, demonstrating a clear
anabolic response [59, 60]. The increased bone formation
induced by romosozumab treatmentwas not associatedwith an
increase in bone resorption. Instead, a decrease of osteoclast
surface was observed, suggesting a functional uncoupling
between bone formation and bone resorption, as also shown in
the studies of SOST knock-out mice. The effect of sclerostin
inhibition on bone formation markers decreased with prolon-
gation of treatment andwas reversible upon its discontinuation.
In phase I human studies, administration of single or
multiple doses of romosozumab and blosozumab increased
bone formation and decreased bone resorption markers
associated with significant increases in BMD [61– 63]. In a
placebo-controlled, dose-escalating study of 72 healthy
men and postmenopausal women, it was shown that a
single injection of romosozumab markedly increased bone
formation markers and BMD and was well tolerated [62].
Serum levels of the bone formation marker P1NP reached a
peak 14–25 days after the antibody administration and
returned progressively to baseline after about 2 months. In
contrast, serum levels of the bone resorption marker CTX
decreased to a minimum about 14 days after the antibody
injection and returned to baseline after about 2 months, in
agreement with animal data.
Recker et al. recently reported the results of a dose-
finding study of blosozumab given subcutaneously for
1 year to 120 postmenopausal women aged 45–85 years
with BMD T-scores between -2.0 and -3.5 [64]. All
women received calcium and vitamin D supplements and
were randomized to receive placebo or blosozumab
(180 mg every 4 weeks, 180 mg every 2 weeks, or 270 mg
every 2 weeks). Blosozumab treatment induced dose-de-
pendent increases in spine BMD by 8.4, 14.9, and 17.0 %,
respectively; TH BMD by 2.1, 4.5, and 6.3 %, respectively;
FN BMD by 2.7, 3.9, and 6.3 %, respectively; and total
body bone mineral content by 1.7, 4.2, and 7.3 %,
respectively, after 1 year; blosozumab treatment had no
effect on BMD of the distal radius. Mild injection site
reactions were more frequently observed with blosozumab
than with placebo and neutralizing antibodies developed in
one patient, which affected her response to treatment.
Although the frequency of adverse events was similar
among all groups, four women (all Japanese) were diag-
nosed with breast cancer between 3 months of initiating
treatment to 1 year after the last dose of blosozumab; none
of the investigators considered this adverse event to be
related to blosozumab treatment.
Results of a phase II clinical trial of the efficacy and
tolerability of romosozumab in postmenopausal women
with low bone mass were also reported [65]. In this
study, different doses and dosing intervals of subcuta-
neous injections of romosozumab were compared with
placebo, oral alendronate 70 mg weekly, and subcuta-
neous teriparatide 20 lg daily. The primary efficacy
point of the study was the change of spine BMD after
12 months. All doses of romosozumab induced signifi-
cant increases in BMD. The highest dose of romo-
suzamab used, 210 mg once monthly, increased BMD at
the spine (11.3 %), TH (4.1 %) and FN (3.7 %). These
increases were significantly higher than those observed
in women treated with either alendronate or teriparatide.
For example, the corresponding increases at the spine
were 4.1 % for alendronate and 7.1 % with teriparatide
after 12 months. No significant differences in BMD of
the distal third of the radius were observed at 12 months
between any of the romosozumab groups and placebo,
alendronate, or teriparatide groups. Adverse events were
similar among all groups of studied women except for
mild reactions at the injection sites of romosozumab.
One patient treated with romosozumab was diagnosed
during the trial with breast cancer that was not consid-
ered to be treatment-related.
Continuation of treatment for a second year was asso-
ciated with further increases in LS and TH BMD to total
gains of 15.7 and 6.0 %, respectively. Women who tran-
sitioned to denosumab after 2 years with romosozumab
continued to accrue BMD at a rate similar to that of
romosozumab during the second year, while in those who
transitioned to placebo, BMD returned towards pretreat-
ment levels; similar results were reported after discontin-
uation of blosozumab [66]. Serum P1NP and CTX levels
remained below baseline values during the second year of
romosozumab treatment [67].
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Kinetics of biochemical markers of bone turnover in
humans and histological data in animals during treatment
with sclerostin inhibitors were different from those
observed during treatment of patients with other antios-
teoporotic agents (Fig. 3). There was an early rapid
increase in bone formation markers followed by a pro-
gressive decline with time which was not due to the
development of neutralizing antibodies. The effect of
sclerostin inhibition on bone formation was further asso-
ciated with a decrease of bone resorption, possibly
through an inhibitory effect of the antibody on the pro-
duction of RANKL by the osteocytes [68]. Treatment
prolongation, however, appears to modestly reduce bone
resorption but also bone turnover. It may, thus, be that
while romosozumab acts as a pure anabolic agent in the
beginning of treatment, its continued administration
results in mild inhibition of bone resorption and reduction
of the remodeling space. Phase III clinical studies are
currently investigating the antifracture efficacy and tol-
erability of romosozumab and blosozumab in patients
with osteoporosis (www.clinicaltrials.gov).
Positioning inhibitors of sclerostin in the management of
patients with osteoporosis will depend not only on their
efficacy in increasing bone mass and reducing the risk of
fractures at all skeletal sites, but also on their safety profile.
The observations that patients with sclerostin deficiency do
not have complications from organs other than the skele-
ton, and that heterozygous carriers do not have any specific
clinical phenotype, are reassuring. However, the number of
these individuals is small and the Wnt-signaling pathway is
involved in growth and differentiation of many cell types
and its activation has been linked to tumorinogenesis,
osteoarthritis, and cardiovascular calcification.
5 Conclusions
The two components of bone remodeling, resorption and
formation, constitute the primary target of pharmacological
interventions for the management of the disease. It is now
clear that bone resorption and formation can be differently
modulated by new classes of antiosteoporotic medications
that provide a novel, personalized perspective for the
management of patients in clinical practice.
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